PGEN logo

PGEN Precigen, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$4.21
+0.05 (+1.20%)

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA cons…

Market Cap: $1.51Bwww.precigen.com

Price

$7.23+73.80%
$3.57$4.79$6.01$7.23
Apr 30Aug 7

Social Signal Score

57
5d
—
30d
59
8 mentions
+0.0%
60d
57
13 mentions
+0.0%
90d
55
16 mentions
+0.0%
news: 16

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 0Buy 11Hold 4Sell 1Strong Sell 0
Avg price target$15+256.3%
Low $12Median $15High $18
Current Consensus

Revenue

$74.15M+61.18%
$717.0K$26.15M$51.59M$77.03M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.11
$-1.27–$-0.94
2 analysts
FY2026
$0.24
$0.23–$0.28
3 analysts
FY2027
$0.63+158% YoY
$0.47–$0.77
3 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Helen Sabzevari
Sector
Healthcare
Industry
Biotechnology
Employees
160
Beta
0.98
Country
US
Piotroski score
5 / 9 (Middling)
Altman Z-score
-5.98
www.precigen.com